Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:clinicalTrialPhase |
NCT02125461
|
| gptkbp:controls |
placebo
|
| gptkbp:designer |
double-blind
randomized multicenter |
| gptkbp:endPoint |
overall survival
progression-free survival |
| gptkbp:firstPublished |
2017
|
| gptkbp:foundIn |
durvalumab improved progression-free and overall survival compared to placebo
|
| gptkbp:fullName |
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
|
| https://www.w3.org/2000/01/rdf-schema#label |
PACIFIC trial
|
| gptkbp:indication |
gptkb:stage_III_non-small_cell_lung_cancer
|
| gptkbp:numberOfPatients |
713
|
| gptkbp:period |
Phase III
|
| gptkbp:population |
patients with unresectable stage III NSCLC without disease progression after chemoradiotherapy
|
| gptkbp:publishedIn |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:region |
international
|
| gptkbp:sponsor |
gptkb:AstraZeneca
|
| gptkbp:startYear |
2014
|
| gptkbp:studiedDrug |
gptkb:durvalumab
|
| gptkbp:bfsParent |
gptkb:Durvalumab
|
| gptkbp:bfsLayer |
6
|